Yintoni iAgonist ekhethekileyo yeDopamine?
Kule nqaku, uya kufunda nge-dopamine ye-agonism. Esi siphumo siboniswe ngokugqithiseleyo yi-aripiprazole (igama lophawu lophawu: i-Abilify), isizukulwana sesibini sokulwa ne-antipsychotic / i-atypical neuroleptic ehluke kuzo zonke ezinye i-antipsychotics ezenzelwa i-atypical eyenziwa ngendlela eyahlukileyo.
I-Aripiprazole ihluke njani kwezinye iAtypicals?
Uninzi lwe-antipsychotics olunomdla olunefuthe olucacileyo lwenkozo yengqondo ye-serotonin kodwa umphumo obuthakathaka kwaye unganqongophe kwi-brain dopamine receptors.
I-Aripiprazole ihluke kuninzi kwezinye iikhemikhali ngokubhekiselele kwindlela yokusebenza. Ngokwenene, i-aripiprazole isebenza nge-dopamine. Ngaloo ndlela, ukusuka kumbono wokusebenza, i-aripiprazole isondele ngakumbi kwi-neuroleptics, okanye i-neuroleptics yokuqala, eyabelana nokuvimba kwe-dopamine kwingqondo (okubizwa ngokuba yi-dopamine antagonism) njengendlela eqhelekileyo yokusebenza.
Ukuba i-Aripiprazole isebenza kwiDopamine Kutheni ibonakaliswa njengeAtypical?
Isizathu sesenzo sokliniki ye-aripiprazole: ingozi yakhe yemiphumo emibi ye-neurological effects ezifana neziqulatho ze-muscular rigidity (i-dystonia) okanye ukungahambi ngokungaqhelekanga kwintlungu (i-dyskinesia) iphantsi, eyayifumana njengeyi-inypical; ngokuchasene nee-antipsychotics ezinobungozi obuphezulu belo hlobo lwemiphumo emibi, ekwahluzwa njengezandi.
I-Aripiprazole yi-dopamine ye-agonist ekhethekileyo-ngokuchasene nomdlali we- dopamine okanye i-blocker njengeyona ndlela yokuqala ye-antipsychotics.
Yintoni i-Dopamine Antagonism?
I-Dopamine yenye yezinto ezifunyenwe nge-neurotransmitters ezifumaneka kwinqanaba le-synaptic, indawo phakathi kwe-neurons. I-Dopamine ikhutshwe kwi-synaptic indawo ukusuka kwi-vesicles ehlala kwi-neuron yangaphambili-synaptic, kwaye ibopha kwi-dopamine receptors kwinqanaba le-postsynaptic neuron.
Cinga nje ngoluhlobo lwenqakrazo kunye nentsimbi ye-effect apho i-dopamine receptors ivuliwe evulekileyo xa i-dopamine "eyona nto" ingena kwisitshixo. Enye yeengcamango ze-schizophrenia kukuba kwiindawo ezithile zengqondo kukho i-dopamine kakhulu kwi-synapse. Iimpawu ezintle ze -schizophrenia zicingelwa ukuba zibangelwa kuzo zonke "i-molecule" ezongezelelweyo ezibophelela kwi-dopamine receptors. Iintsholongwane zeDopamine zibophelela kwi-dopamine receptors, ngaloo ndlela zivimbela i-dopamine ebophayo. Kwaye ngaphandle kwesiqhosha esifanelekileyo, oko kukuthi i-dopamine, isitshixo asivuli - ngamanye amagama, njengoko ingxaki ephezulu yodopamine ilungiswa kwinqanaba le synapse akukho miphumo emibi (iimpawu ezintle) ezibangelwa kuyo. Nangona kunjalo ingxaki kukuba i-dopamine ivimbela yonke ingqondo xa i-dopamine engaphezu kwe-schizophrenia iphela kwiindawo ezithile zobuchopho. Ngokuqhubekayo, kwi-schizophrenia, ngelixa ezinye iinxalenye zobomi zixhomekeke kwi-dopamine ngokweqile, ezinye iindawo zijongene nokulahleka kwe-dopamine. Iintsholongwane ze-Dopamine azigcini nje ukuvimba i-receptors kwindawo apho kukho ubuninzi kodwa nakwiindawo apho kungekho dopamine eyaneleyo. Yingakho la mayeza, ngelixa esebenzayo kwimpawu ezintle - ngenxa yokukhusela i-receptors kwingingqi yengqondo ephethe i-dopamine eninzi, ithambekele ekwandiseni iimpawu ezimbi , imiba engqondweni, kunye nomngcipheko we-parkinsonism kwizigulane ezithathayo, ngenxa yokuvala ye-dopamine kwingingqi yengqondo apho kungekho dopamine encinane.
Isisombululo esinokusifumana kule ngxaki sisebenzisa i-agonists.
Yiyiphi iAgonist ekhethekileyo yeDopamine?
I-dopamine ye-dopamine i-agonist yi-molecule ebopha kwi-receptor kwaye iyayisebenzisela. Cinga ngolu hlobo njengesihluthulelo sokuthi ulungele ukungena kwi-lock ukwenzela ukuba umnyango ungashenxiswa kodwa ungavuli ngokupheleleyo. Impembelelo ye-agonist ye-dopamine yincinci ingaphantsi komphumo opheleleyo we-dopamine kodwa ngaphezu kokusilela ngokupheleleyo, oko kwenzekayo xa i-receptor ivalwe ngokupheleleyo. Ngamanye amagama, impembelelo ekhethekileyo. Esi siphumo sincinci sithetha ukuba xa kuninzi i-dopamine ecaleni kwe-aripiprazole (i-dopamine ye-agonist eyingxenye) ngokuthatha indawo ye-dopamine kwi-receptors kwaye ibenze i-activation kuphela iyakuthi ithathe umphumo we-dopamine kakhulu.
Kwakhona kuthetha ukuba kwiimeko apho kukho i-dopamine encinci ukuza kusebenze yonke i-recepters receptors aripiprazole iya kubophelela kwi-receptors engabanjwanga kunye nempembelelo yayo, nangona ikhethe kuphela, ngoku idibene kwi-dopamine yempembelelo kwi-synapse ukwenyuka kwenyusa umphumo we-dopaminergic we-dapamine-i-synapse ekhuselekile.
Ukufingqa, i-aripiprazole, njenge-dopamine i-agonist eyingxenye, isebenza njengomodulator of effects of dopamine. Xa sikhona, iyanciphisa imiphumo ye-dopamine ngokweqile (ngokunciphisa isenzo se-dopamine xa kuninzi kakhulu) kunye nesikhokelo (ngokunyusa isenzo se-dopamine xa kuncinci kakhulu).
U kufunda ngakumbi
UAarvid Carlsson: I-dopaminergic deficit hypothesis ye-schizophrenia: indlela yokufumana. Iingxoxo zeKlinikhi ye-Neurosci. Mar 2006; 8 (1): 137-142